{
  "id": 6274868,
  "title": "With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems",
  "url": "https://urgent.news/2026/09/08/with-116m-in-series-a-financing-brainchild-bio-targets-cns-tumors",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T11:00:14.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/cancer/with-116m-in-series-a-financing-brainchild-bio-targets-cns-tumors-starting-with-one-in-childrens-brainstems/"
  },
  "original_language": "en",
  "account": "BrainChild Bio has secured $116 million in Series A financing to advance its lead candidate for pediatric brainstem tumors, specifically diffuse intrinsic pontine glioma (DIPG). The financing will support the pivotal registrational Phase II ILLUMINATE trial, which will evaluate the efficacy and safety of BCB-276, an autologous chimeric antigen receptor (CAR) T cell therapy, in treating newly diagnosed DIPG patients who have undergone initial standard-of-care focal radiation therapy. BCB-276 targets B7-H3, an immune checkpoint protein that has been linked to tumor progression and immune evasion, and is highly expressed in up to 93% of DIPG cases. The drug has demonstrated promising results in a Phase I trial, extending median time to death from 19.8 months for all patients, compared to the 8–11-month median survival associated with current standard-of-care treatment. BrainChild Bio CEO Steven Brugger stated that the trial patients will begin BCB-276 treatment as soon as possible after radiation. The FDA has also shown support for BrainChild Bio's efforts, designating BCB-276 for Fast Track designation and agreeing to the single-arm design of the ILLUMINATE trial. Despite the positive developments, BrainChild Bio has faced challenges in attracting institutional investors for the Series A financing, with the company instead relying on limited options from non-traditional investors.",
  "summary": "BCB-276 is designed to treat diffuse intrinsic pontine glioma (DIPG) by targeting B7-H3, an immune checkpoint protein encoded by the CD276 gene that has been shown to be involved in tumor progression and immune evasion and is highly expressed in anywhere from 60% of solid tumor samples up to 93%, according to past studies cited by BrainChild Bio. The post With $116M in Series A Financing,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}